The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

被引:0
|
作者
Robin L Carhart-Harris
Guy M Goodwin
机构
[1] Psychedelic Research Group,Division of Brain Sciences
[2] Centre for Psychiatry,University of Oxford Department of Psychiatry and Oxford Health NHS Foundation Trust
[3] Faculty of Medicine,undefined
[4] Imperial College London,undefined
[5] Warneford Hospital,undefined
来源
Neuropsychopharmacology | 2017年 / 42卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.
引用
收藏
页码:2105 / 2113
页数:8
相关论文
共 50 条
  • [1] The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
    Carhart-Harris, Robin L.
    Goodwin, Guy M.
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 (11) : 2105 - 2113
  • [2] Psychiatry & the psychedelic drugs. Past, present & future
    Rucker, James J. H.
    Iliff, Jonathan
    Nutt, David J.
    NEUROPHARMACOLOGY, 2018, 142 : 200 - 218
  • [3] Back to the Future - The Therapeutic Potential of Psychedelic Drugs
    Lieberman, Jeffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15): : 1460 - 1461
  • [4] Neuroimaging in psychedelic drug development: past, present, and future
    Wall, Matthew B.
    Harding, Rebecca
    Zafar, Rayyan
    Rabiner, Eugenii A.
    Nutt, David J.
    Erritzoe, David
    MOLECULAR PSYCHIATRY, 2023, 28 (09) : 3573 - 3580
  • [5] PSYCHEDELIC-ASSISTED PSYCHOTHERAPY: THE PAST, THE PRESENT, THE FUTURE
    Puspanathan, P.
    Sekula, A. D.
    Starke, J.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2022, 56 (1_SUPPL): : 56 - 57
  • [6] Psychedelic therapy in the treatment of addiction: the past, present and future
    Zafar, Rayyan
    Siegel, Maxim
    Harding, Rebecca
    Barba, Tommaso
    Agnorelli, Claudio
    Suseelan, Shayam
    Roseman, Leor
    Wall, Matthew
    Nutt, David John
    Erritzoe, David
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [7] Neuroimaging in psychedelic drug development: past, present, and future
    Matthew B. Wall
    Rebecca Harding
    Rayyan Zafar
    Eugenii A. Rabiner
    David J. Nutt
    David Erritzoe
    Molecular Psychiatry, 2023, 28 : 3573 - 3580
  • [8] Drugs, past, present, and future
    Kaye, Alan D.
    CURRENT OPINION IN ANESTHESIOLOGY, 2008, 21 (04) : 425 - 426
  • [9] ANTIDIABETIC DRUGS - PAST, PRESENT AND FUTURE
    LOUBATIE.A
    ACTA DIABETOLOGICA LATINA, 1973, 10 (02): : 389 - 389
  • [10] Antiarrhythmic drugs: Past, present, and future
    Roden, DM
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2003, 26 (12): : 2340 - 2349